VivoSeq
Infectious Disease

Chronic Hepatitis B Virus Infection

73

Pipeline Programs↗

11

Active Trials↗

32

Companies Involved↗

Chronic Hepatitis B Virus Infection is a moderately active landscape with 73 programs across 32 companies. The most active players are Roche, Enanta Pharmaceuticals, Inc, AstriVax Therapeutics. 8 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

19/100

Mech. Concentration

18/100

Completion Rate

66/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

3 programs

Phase 1E

Enanta Pharmaceuticals, Inc

2 programs

Phase 1A

AstriVax Therapeutics

1 program

Phase 1S

Shanghai Longwood Biopharmaceuticals Co., Ltd.

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 1S

Suzhou HepaThera Biotech Co., Ltd.

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

69 of 77 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody45%Vaccine23%Protein / enzyme11%RNA therapy11%

Small molecule leads; the ring shows all 77 classified programs, each share of the total. Modality classified for 98% of 83 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed23 · 47%
Terminated12 · 24%
Recruiting5 · 10%
Active, not recruiting5 · 10%
Unknown status3 · 6%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

49 trials

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
Recruiting·Gilead logoGilead·Phase 2·NCT02932150·150 enrolled
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05769816·120 enrolled
Methylene Blue Treatment of Chronic Hepatitis B Virus Infection
Recruiting·FFondazione Epatocentro Ticino·Phase 2·NCT06887036·10 enrolled
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of Single and Multiple Ascending Doses of IB-001 in Healthy Participants and Participants With Chronic Hepatitis B
Recruiting·IIntegerBio·Phase 1·NCT07389044·80 enrolled
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
Active, not recruiting·AAstriVax Therapeutics·Phase 1·NCT06989788·16 enrolled
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
Active, not recruiting·SSuzhou HepaThera Biotech Co., Ltd.·Phase 2·NCT07245953·60 enrolled
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT04856085·244 enrolled
A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection
Active, not recruiting·SSuzhou HepaThera Biotech Co., Ltd.·Phase 1/2·NCT07183306·86 enrolled
A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)
Active, not recruiting·GSK logoGSK·Phase 2·NCT06537414·283 enrolled
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
Not yet recruiting·VVaxine Pty Ltd·Phase 1/2·NCT03038802·40 enrolled
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT04470388·25 enrolled
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT03361956·232 enrolled
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
Completed·AAntios Therapeutics, Inc·Phase 1·NCT04248426·88 enrolled
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05242445·11 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)